Efficacy, Safety and Tolerability of XBD173 in Patients With Generalized Anxiety Disorder

ClinicalTrials.gov ID: NCT00108836

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00108836. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:17 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will test the efficacy, safety and tolerability of XBD173 in the treatment of generalized anxiety disorder in patients.

Study identification

NCT ID: NCT00108836
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Novartis Pharmaceuticals; Industry
Enrollment: 400 participants

Conditions and interventions

Conditions

Anxiety Disorders

Interventions

XBD173 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 65 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 2005 (Type not available)
Primary completion: Not listed
Completion: May 2006 (Actual)
Last update posted: May 20, 2010

2005 – 2006

United States locations

U.S. sites: 16
U.S. states: 8
U.S. cities: 16

Facility	City	State	ZIP	Site status
Investigational Site	Anaheim	California	92801	—
Investigational Site	Los Angeles	California	90024	—
Investigational Site	Newport Beach	California	92660	—
Investigational Site	Redlands	California	92374	—
Investigational Site	San Diego	California	92108	—
Investigational Site	Fort Meyers	Florida	33712	—
Investigational Site	St. Petersburg	Florida	33702	—
Investigational Site	West Palm Beach	Florida	33407	—
Investigational Site	Atlanta	Georgia	30308	—
Investigational Site	Hoffman Estates	Illinois	60194	—
Investigational Site	Oak Brook	Illinois	60523	—
Investigational Site	Overland Park	Kansas	66211	—
Investigational Site	Dayton	Ohio	45408	—
Investigational Site	Portland	Oregon	97239	—
Investigational Site	Madison	Tennessee	37115	—
Investigational Site	Memphis	Tennessee	38119	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00108836, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 20, 2010 · Synced Nov 15, 2026